Chemistry:Emibetuzumab
From HandWiki
Short description: Monoclonal antibody
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | HGFR |
Clinical data | |
Other names | LY2875358 |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6356H9810N1694O2014S48 |
Molar mass | 143719.12 g·mol−1 |
Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3]
This drug was developed by Eli Lilly & Company.
References
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111". WHO Drug Information 28 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.
- ↑ "A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.". http://meetinglibrary.asco.org/content/164953-176.
![]() | Original source: https://en.wikipedia.org/wiki/Emibetuzumab.
Read more |